Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACP-103 Extension Study in Parkinson's Disease Psychosis
NCT00550238Phase 3Completed
- Sponsor
- Acadia Pharmaceuticals
- Start
- Jul 2007
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 3 trial of pimavanserin in Parkinson's disease (PD), sponsored by Acadia Pharmaceuticals. Started Jul 2007; status: completed.
02
Drugs
pimavanserin
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT00550238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00550238.